320 Park Avenue
NY 10022 New York
+1 (212) 271-0861
DBV Technologies Reports December 31, 2016 Cash Position
Full year 2016 financial results will be announced on March 15, 2017.
Cash and cash equivalents
DBV's cash and cash equivalents amounted to €256.5 million as of December 31, 2016, compared to €323.4 million as of December 31, 2015.
Number of outstanding and fully diluted shares
As of December 31, 2016, DBV's number of outstanding shares was 24,648,828 ordinary shares and on a fully diluted basis, the number of shares was 27,255,263.
 fully diluted share capital represents all issued and outstanding shares, as well as all potential shares which may be issued upon exercise of outstanding employee warrants, employee free shares and share options and nonemployee warrants, as approved by DBV Technologies shareholders and granted by the board of directors.
Forward Looking Statements
This press release may contain forward-looking statements and estimates. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.